



Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder



Kim L. Gratz^{a,*}, Joseph R. Bardeen^b, Roy Levy^c, Katherine L. Dixon-Gordon^a, Matthew T. Tull^a

^a Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA

^b Department of Psychology, Auburn University, Auburn, AL, USA

^c T. Denny Sanford School of Social and Family Dynamics, Arizona State University, Tempe, AZ, USA

ARTICLE INFO

Article history:

Received 25 May 2014

Received in revised form

6 October 2014

Accepted 5 December 2014

Available online 13 December 2014

Keywords:

Borderline personality

Treatment

Group therapy

Self-injury

Mechanisms of change

Emotion regulation

ABSTRACT

Despite growing evidence for the efficacy of Gratz and colleagues' emotion regulation group therapy (ERGT) for deliberate self-harm (DSH) among women with borderline personality disorder (BPD), the proposed mechanism of change in this treatment (i.e., emotion regulation) remains largely unexamined. This study examined change in emotion dysregulation as a mediator of the effects of this ERGT on DSH and BPD symptoms, as well as the extent to which change in emotion dysregulation during treatment predicts further improvements in DSH during a 9-month follow-up. Participants included 61 female outpatients with BPD and recent DSH who were randomly assigned to receive this ERGT in addition to their ongoing outpatient therapy immediately ($n = 31$) or after 14 weeks ($n = 30$). Measures of emotion dysregulation, DSH, and BPD symptoms were administered pre- and post-treatment or -waitlist, and at 9-months post-treatment (for participants in both conditions who received ERGT). Results from a series of mediation analyses provide further support for emotion regulation as a mechanism of change in this treatment. Specifically, results revealed that improvements in emotion dysregulation over the course of treatment mediated the observed reductions in BPD cognitive and affective symptoms during treatment and predicted further improvements in DSH during follow-up.

© 2014 Elsevier Ltd. All rights reserved.

Introduction

Deliberate self-harm (DSH; also referred to as nonsuicidal self-injury), defined as the deliberate, direct, self-inflicted destruction of body tissue without suicidal intent and for purposes not socially sanctioned (e.g., cutting, burning, severe scratching; Gratz, 2001; ISSS, 2007), is a clinically-important behavior commonly associated with borderline personality disorder (BPD; Linehan, 1993) and implicated in the high levels of health care utilization among individuals with BPD (Zanarini, 2009). Despite the clinical relevance of this behavior, there are few empirically-supported treatments

for DSH within BPD. Short-term treatments for DSH in general have not been found to be effective for patients with BPD, and may lead to an increase in the repetition of DSH among individuals with BPD (Tyroner et al., 2004). Moreover, the two treatments with demonstrated efficacy in the treatment of DSH among patients with BPD, Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mentalization-Based Treatment (Bateman & Fonagy, 2004), are difficult to implement in traditional clinical settings (due to their duration and intensity) and are not readily available in many communities (Zanarini, 2009). Thus, there is a need for shorter, less intensive, and more clinically feasible interventions that directly target DSH among individuals with BPD, particularly adjunctive treatments that may augment the therapies provided by clinicians in the community (Zanarini, 2009).

To address this need, Gratz and colleagues (Gratz & Gunderson, 2006; Gratz & Tull, 2011) developed an adjunctive emotion regulation group therapy (ERGT) for DSH among women with BPD, designed to augment the usual treatments provided in the community by

* Corresponding author. Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. Tel.: +1 601 815 6450; fax: +1 601 984 4489.

E-mail addresses: klgratz@aol.com (K.L. Gratz), jbardeen@auburn.edu (J.R. Bardeen), roy.levy@asu.edu (R. Levy), katedg@gmail.com (K.L. Dixon-Gordon), mtull@umc.edu (M.T. Tull).

directly targeting both DSH and its underlying mechanism. Specifically, drawing on theoretical and empirical literature highlighting the central role of emotion dysregulation in the development and maintenance of DSH (e.g., Chapman, Gratz, & Brown, 2006; Gratz, 2007; Gratz & Gunderson, 2006; Gratz & Roemer, 2008; Gratz & Tull, 2010b; Heath, Toste, Nedecheva, & Charlebois, 2008; Linehan, 1993; Slee, Spinhoven, Garnefski, & Arensman, 2008), this ERGT was developed with the expectation that teaching self-harming women with BPD more adaptive ways of responding to and regulating their emotions would reduce their DSH.

Table 1
Pretreatment demographic, clinical, and diagnostic data for intent-to-treat sample.

	ERGT + TAU (n = 31)	TAU waitlist (n = 30)
Demographic characteristics		
Age	mean = 33.3 ± 11.0	mean = 33.0 ± 10.9
Racial/ethnic minority	16.1% (n = 5)	26.7% (n = 8)
Lesbian/bisexual/questioning	12.9% (n = 4)	13.7% (n = 4)
Marital status		
Single	51.7% (n = 16)	56.7% (n = 17)
Married	25.8% (n = 8)	13.3% (n = 4)
Separated/Divorced	22.6% (n = 7)	30.0% (n = 9)
Highest educational attainment		
Less than high school	6.5% (n = 2)	6.7% (n = 2)
High school graduate	54.8% (n = 17)	73.3% (n = 22)
College graduate	25.8% (n = 8)	16.7% (n = 5)
Income		
<\$20,000	38.7% (n = 12)	57.1% (n = 16)
\$20,000–\$59,999	32.3% (n = 10)	32.1% (n = 9)
>\$60,000	29.0% (n = 9)	10.7% (n = 3)
Clinical characteristics		
Number of BPD criteria (DIPD-IV)	mean = 6.5 (SD = 1.6)	mean = 6.0 (SD = 1.5)
% meeting full criteria for BPD	90.3% (n = 28)	86.7% (n = 26)
Suicide attempt in lifetime	58.1% (n = 18); range = 0–16	66.7% (n = 20); range = 0–5
Suicide attempt past year	16.1% (n = 5); range = 0–2	20.0% (n = 6); range = 0–2
DSH frequency in past 3 mos.	Mean = 35.5 ± 68.4	Mean = 28.4 ± 39.4
Inpatient hospitalization past year	12.9% (n = 4)	26.7% (n = 8)
Total hours/week of ongoing therapy	mean = 1.2 (SD = 1.4)	mean = 2.5 (SD = 2.6)
Hours/week individual therapy	mean = 0.7 (SD = 0.4)	mean = 1.0 (SD = 0.8)
Hours/week group therapy	mean = 0.4 (SD = 1.3)	mean = 0.6 (SD = 1.8)
Number psychiatric medications	mean = 1.9 (SD = 1.7)	mean = 2.1 (SD = 1.2)
Number mos. with individual therapist	mean = 15.5 (SD = 19.3)	mean = 14.9 (SD = 25.4)
Global Assessment of Functioning score	mean = 43.4 (SD = 24.6)	mean = 40.5 (SD = 19.8)
Diagnostic data		
Lifetime Axis I disorders		
Mood disorder	80.6% (n = 25)	86.7% (n = 26)
Substance use disorder	54.8% (n = 17)	60.0% (n = 18)
Anxiety disorder	74.2% (n = 23)	86.7% (n = 26)
Posttraumatic Stress Disorder	48.4% (n = 15)	63.3% (n = 19)
Eating disorder	36.7% (n = 11)	42.9% (n = 12)
Current Axis I disorders		
Mood disorder	41.9% (n = 13)	60.0% (n = 18)
Substance use disorder	0.0% (n = 0)	3.3% (n = 1)
Anxiety disorder	54.8% (n = 17)	70.0% (n = 21)
Posttraumatic Stress Disorder	29.0% (n = 9)	43.3% (n = 13)
Eating disorder	16.7% (n = 5)	10.7% (n = 3)
Axis II comorbidity		
Cluster A PD	6.7% (n = 2)	10.0% (n = 3)
Cluster B PD (other than BPD)	13.3% (n = 4)	20.0% (n = 6)
Cluster C PD	36.7% (n = 11)	43.3% (n = 13)

Note. None of the above demographic, clinical, or diagnostic variables differed significantly between conditions ($t_s < 1.50$, $\chi^2_s < 3.49$, $p_s > .15$), with the exception of total hours/week of ongoing therapy.

To date, three studies have provided support for the utility of this ERGT in the treatment of DSH among women with BPD, including an open trial (Gratz & Tull, 2011) and two randomized controlled trials (Gratz & Gunderson, 2006; Gratz, Tull, & Levy, 2014). The most recent of these, a larger randomized controlled trial (RCT) and uncontrolled 9-month follow-up (see Gratz et al., 2014), provided further evidence for the efficacy of this adjunctive ERGT (relative to a treatment as usual [TAU] only waitlist condition), revealing positive effects of this treatment on both the primary treatment targets (i.e., DSH, emotion dysregulation, and BPD symptoms) and other relevant outcomes (i.e., depression and stress symptoms, and overall quality of life) within a conservative intent-to-treat (ITT) sample. Moreover, findings from the 9-month follow-up period provide preliminary support for the durability of treatment gains, as all improvements observed from pre-to post-treatment were maintained or further improved upon at follow-up, including additional significant improvements from post-treatment through 9-month follow-up for DSH, emotion dysregulation, and BPD symptoms (among others; Gratz et al., 2014).

Despite growing evidence for the efficacy of this ERGT for DSH within BPD, the proposed mechanism of change in this treatment remains largely unexamined, with only one study to date examining the mediating role of emotion regulation in improvements in DSH over the course of this treatment (Gratz, Levy, & Tull, 2012). However, such research has the potential to elucidate both the precise role of emotion dysregulation in the course of DSH and the clinical utility of targeting emotion dysregulation in the treatment of DSH among women with BPD (thereby providing important information on how best to optimize therapeutic change for this population; Kazdin, 2007). Thus, this study utilized data from the most recent RCT to examine emotion regulation as the mechanism of change in this treatment. Specifically, this study examined change in emotion dysregulation as a mediator of the effects of this ERGT on DSH and BPD symptoms, as well as the extent to which change in emotion dysregulation during treatment predicted further improvements in DSH from post-treatment through the 9-month follow-up. We hypothesized that change in emotion dysregulation would mediate the reductions in DSH frequency and BPD symptom severity observed over the course of treatment and predict further improvements in DSH during the follow-up period.

Method

Sample and procedures

All methods were approved by the institution's Institutional Review Board. Participants were obtained through referrals by clinicians and self-referrals in response to advertisements for an "emotion regulation skills group for women with self-harm" posted online and throughout the community. Inclusion criteria included: (a) threshold or subthreshold diagnosis of BPD (given evidence that even subthreshold BPD is clinically-meaningful; Clifton & Pilkonis, 2007); (b) a history of repeated DSH, with at least one episode in the past six months; (c) having an individual therapist, psychiatrist, or case manager; and (d) being a woman aged 18–60. To increase generalizability of the sample, exclusion criteria included only diagnoses of a primary psychotic disorder, bipolar I disorder, and current (past month) substance dependence. Participants meeting inclusion and exclusion criteria were matched on four prognostic variables (emotion dysregulation, number of lifetime incidents of DSH, global assessment of functioning scores, and age) and randomly assigned by the principal investigator (PI) to either the ERGT + TAU (n = 31) or TAU waitlist (n = 30) condition using a stratified randomization procedure. See Table 1 for demographic, clinical, and diagnostic data on participants in each condition.

متن کامل مقاله

دریافت فوری ←

ISIArticles

مرجع مقالات تخصصی ایران

- ✓ امکان دانلود نسخه تمام متن مقالات انگلیسی
- ✓ امکان دانلود نسخه ترجمه شده مقالات
- ✓ پذیرش سفارش ترجمه تخصصی
- ✓ امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
- ✓ امکان دانلود رایگان ۲ صفحه اول هر مقاله
- ✓ امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
- ✓ دانلود فوری مقاله پس از پرداخت آنلاین
- ✓ پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات